Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRAS | P01112 | 1/20 | 0.39 |
| ▸ | HEXA | P06865 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980659 | 0.94 | LMNA (0.41) | LMNASMN1; SMN2HRASHEXAHTT | |
| SCHEMBL30980620 | 0.91 | HRAS (0.39) | LMNASMN1; SMN2HRASHEXA | |
| SCHEMBL31078937 | 0.85 | HRAS (0.38) | LMNASMN1; SMN2HRASHEXA | |
| SCHEMBL30980568 | 0.84 | MAPK1 (0.38) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30980607 | 0.81 | MDK (0.40) | LMNASMN1; SMN2HRASHEXA | |
| SCHEMBL30980624 | 0.79 | MAPK1 (0.52) | LMNASMN1; SMN2HRASMEN1KMT2A | |
| SCHEMBL30980682 | 0.79 | CA1 (0.35) | — | |
| SCHEMBL30980709 | 0.79 | MAPK1 (0.41) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL24239904 | 0.78 | LMNA (0.52) | LMNASMN1; SMN2HRASMEN1KMT2A | |
| SCHEMBL30980649 | 0.76 | MAPK1 (0.43) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024155747-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |